Literature DB >> 20359471

Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers.

P Boor1, P Celec, K Klenovicsová, B Vlková, T Szemes, G Minárik, J Turna, K Sebeková.   

Abstract

BACKGROUND: The receptor for advanced glycation end-products (RAGEs) and its gene polymorphisms are implicated in the pathogenesis of different chronic diseases including diabetes and its complications. Infant formulas contain high amounts of advanced glycation end-products (AGEs) - the ligands of RAGE.
METHODS: In this cross-sectional study, we examined the impact of G82S and -374 A/T polymorphisms in the gene encoding RAGE on standard blood chemistry, soluble (s)RAGE and inflammatory markers in 244 healthy infants (3-16months of age) and in 119 healthy mothers. Children were subdivided according to age (younger and older than 8months) and for the -374 A/T polymorphism according to the feeding regimen (breast-fed vs. infant formula-fed).
RESULTS: Minor allele of the RAGE gene polymorphism G82S was associated with reduced plasma sRAGE in all age groups and with increased sICAM-1 in older children and mothers. Minor allele carrying mothers had decreased insulin sensitivity and HDL. The A allele of the RAGE gene promoter polymorphism -374 A/T was associated with higher indices of insulin resistance in young infant formula-fed, but not breast-fed children. In older, formerly infant formula-fed children signs of insulin resistance diminished, while formerly breast-fed children with A allele were more insulin sensitive.
CONCLUSIONS: The phenotype of minor allele carriers in G82S is associated with reduced levels of protective sRAGE in healthy infants. With increasing age sICAM-1 levels increased and insulin resistance developed. In early childhood the phenotype of the -374 A/T polymorphism was diet-dependently associated with changes in glucose metabolism, which diminished with increasing age. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359471     DOI: 10.1016/j.cca.2010.03.033

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study.

Authors:  Radana Gurecká; Ivana Koborová; Melinda Csongová; Jozef Šebek; Katarína Šebeková
Journal:  Glycoconj J       Date:  2016-06-14       Impact factor: 2.916

Review 2.  RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.

Authors:  Gowri Palanissami; Solomon F D Paul
Journal:  Horm Cancer       Date:  2018-07-09       Impact factor: 3.869

3.  Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.

Authors:  Emily A Oliver; Catalin S Buhimschi; Antonette T Dulay; Margaret A Baumbusch; Sonya S Abdel-Razeq; Sarah Y Lee; Guomao Zhao; Shichu Jing; Christian M Pettker; Irina A Buhimschi
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

Review 4.  Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children.

Authors:  Anshu Gupta; Jaime Uribarri
Journal:  Horm Res Paediatr       Date:  2016-03-19       Impact factor: 2.852

Review 5.  Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism.

Authors:  Marine Serveaux-Dancer; Matthieu Jabaudon; Isabelle Creveaux; Corinne Belville; Raïko Blondonnet; Christelle Gross; Jean-Michel Constantin; Loïc Blanchon; Vincent Sapin
Journal:  Dis Markers       Date:  2019-02-04       Impact factor: 3.434

6.  Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption.

Authors:  Kristína Simon Klenovics; Peter Boor; Veronika Somoza; Peter Celec; Vincenzo Fogliano; Katarína Sebeková
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.